All Artificial Intelligence (AI) articles – Page 14
-
ArticlePart four: an industry leader’s perspective on managing data quality
In this four-part series, Dr Raminderpal Singh discusses the challenges surrounding limited data quality and offers some pragmatic solutions. In this fourth article, he talks to John Conway, Chief Visioneer Officer at 20/15 Visioneers for an expert perspective.
-
ArticleInitial in vivo validation of novel cancer therapeutics using AI
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy ...
-
ArticleOvercoming operational challenges in CGT manufacturing with AI
In this Q&A, Dalip Sethi, scientific lead for Terumo Blood and Cell Technologies, Cell Therapy Technologies and Innovation portfolio, discusses the integration of AI into CGT manufacturing processes to enhance operational efficiency and accelerate treatment access. He also elucidates the strategies that are being considered to overcome hurdles when implementing ...
-
NewsNew network model efficiently identifies cancer driver genes
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
-
WebinarOvercoming critical challenges in AI-driven drug discovery
The increasing use of AI in the life science field marks a pivotal point in history. Although AI is now an indispensable tool in drug discovery, promising to save vast amounts of time and money, there are still many hurdles scientists encounter. This webinar will explore these challenges and offer ...
-
NewsSino Biological and BioGeometry: advancing protein R&D
The expansion of Sino Biological and BioGeometry’s strategic partnership promises to accelerate drug discovery.
-
ArticlePart three: 15 pragmatic guidelines to handle data quality issues
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this third article, he discusses pragmatic guidelines to help support better data quality.
-
News
New AI tool accurately portrays metabolic states
RENAISSANCE can quantify unknown intracellular metabolic states, including metabolic fluxes.
-
ArticlePart two: the impact of poor data quality
In this four-part series, Dr Raminderpal Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this second article, he discusses the problems that occur when using data of poor quality.
-
NewsOvercoming the limitations of existing AI models
Researchers have developed a new AI tool which recognises that protein behaviour can vary by cell and by tissue type.
-
ArticlePart one: an introduction to data quality
In this four-part series, Dr Singh will discuss the challenges surrounding limited data quality, and some pragmatic solutions. In this first article, the key attributes that define data quality and its requirement for data scientists are elucidated.
-
ArticleThe art and science of drug formulation
Drug formulation is a cornerstone of modern medicine, turning raw active ingredients into consumable, effective therapies. This critical phase in drug development ensures that medications are safe, effective, and user-friendly. Here Ningfeng Fiona Li, founder and CEO of VasoDynamics, explores the world of drug formulation from its foundations to exploring ...
-
News
Improving the effectiveness of immunotherapy for glioblastoma
Researchers utilised AI to identify genes that reprogramme GBM cancer cells into dendritic cells within the tumour.
-
WebinarUnprecedented fragment-based screening using Spectral Shift for GPCRs
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.
-
ArticlePart three: pragmatic guidelines to getting the best out of LLMs
There have been a slew of announcements over the past few months from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the third of a three-part series, Dr Raminderpal Singh presents some pragmatic guidelines for scientists in accessing and obtaining value from LLMs.
-
ArticlePart two: how ChatGPT enriched animal study results
Recently there has been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the second of a three-part series, Dr Raminderpal Singh presents an example of usage of ChatGPT, which demonstrates how accessible LLMs have become for lab scientists.
-
NewsCapturing the computational abilities of real neurons
A new neural network computational model has been developed, which more closely reflects the abilities of real neurons and could advance AI progress.
-
NewsAI tool identifies high-risk subtype of endometrial cancer
The tool identified patients with high-risk disease, which normally goes unrecognised by traditional diagnostics.
-
NewsThe potential of deep learning: generating drug targets
Researchers have designed synthetic, soluble versions of cell membrane proteins, which will enable faster and easier screening for new drugs.
-
ArticleChanging the paradigm of drug discovery processes with AI
We had the privilege of speaking to Cellarity’s CEO, Fabrice Chouraqui, about how the company is leveraging AI to completely revolutionise the drug discovery process and unlock treatments for a vast array of diseases, even in the absence of known targets.